Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19

Jeyaraman, Madhan and John, Albin and Koshy, Santhosh and Ranjan, Rajni and Anudeep, Talagavadi Channaiah and Jain, Rashmi and Swati, Kumari and Jha, Niraj Kumar and Sharma, Ankur and Kesari, Kavindra Kumar and Prakash, Anand and Nand, Parma and Jha, Saurabh Kumar and Reddy, P. Hemachandra (2021) Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1867 (2). 166014. ISSN 1879-260X (https://doi.org/10.1016/j.bbadis.2020.166014)

[thumbnail of Jeyaraman-etal-BBAMBD-2020-Fostering-mesenchymal-stem-cell-therapy-to-halt-cytokine-storm-in-COVID-19]
Preview
 Text. Filename: Jeyaraman_etal_BBAMBD_2020_Fostering_mesenchymal_stem_cell_therapy_to_halt_cytokine_storm_in_COVID_19.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (7MB)| Preview

Abstract

The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11th of March 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19.

ORCID iDs

Jeyaraman, Madhan, John, Albin, Koshy, Santhosh, Ranjan, Rajni, Anudeep, Talagavadi Channaiah, Jain, Rashmi, Swati, Kumari, Jha, Niraj Kumar, Sharma, Ankur ORCID logoORCID: https://orcid.org/0000-0003-3058-760X, Kesari, Kavindra Kumar, Prakash, Anand, Nand, Parma, Jha, Saurabh Kumar and Reddy, P. Hemachandra;
  • Item type:Article
    ID code:83124
    Dates:
    Date
    Event
    1 February 2021
    Published
    1 December 2020
    Published Online
    6 November 2020
    Accepted
    Subjects:Science > Microbiology > Virology
    Department:UNSPECIFIED
    Depositing user: Pure Administrator
    Date deposited:09 Nov 2022 10:14
    Last modified:11 Nov 2024 13:39
    Related URLs:
    URI:https://strathprints.strath.ac.uk/id/eprint/83124
CORE (COnnecting REpositories)